Mobile website
Basic Research
Survivin is involved in drug resistance of pancreatic cancer PaTu8988 cells to gemcitabine
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To explore the expression of apoptotic inhibitory protein survivin in pancreatic cancer cell line PaTu8988, and to study its role in the drug resistance of PaTu8988 cells to gemcitabine (GEM). Methods: The inhibitory effect of GEM (0.01, 0.1, 1.0, 2.5, 5.0, and 10.0 μg/ml) on PaTu8988 cells was detected by MTT assay; apoptosis rate of PaTu8988 cells treated with GEM was determined by flow cytometry; and the survivin mRNA expression in PaTu8988 cells was examined by RT-PCR. Results: High dosage of GEM (≥1.0 μg/ml) greatly inhibited growth and promoted apoptosis of PaTu8988 cells, while low dosage of GEM (0.01, 0.1 μg/ml) showed no effects. Low dose of GEM time-dependently increased expression of survinin mRNA in PaTu8988 cells; high dosage of GEM gradually inhibited survivin mRNA expression within the first 48 h, and then survivin mRNA expression gradually increased as time went by. Conclusion: Survivin mRNA is highly expressed in pancreatic cancer cell line PaTu8988, which may be one of the reasons for drug resistance to GEM.
Keywords:
Project Supported:
Project supported by the Major Medical Science and Technology Development Program of Nanjing Medical University（No. 08NMUZ042）
Clc Number:
